Endpoint Selection Still An Issue For Publication-Based NDAs
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee Sept. 13 indicated approval for currently marketed phenylephrine to treat hypotension in the peri-operative setting based on the ability to increase blood pressure, but voted 8-2 against its use in shock because of the need for outcomes data.
You may also be interested in...
Economics Of Gaining Approval For Unapproved Phenylephrine Remains Question Mark
West-Ward could be the first to gain approval for phenylephrine in hypotension, but the drug’s widespread use as a stand-by medication during surgery could deter FDA enforcement against unapproved versions.
Phenylephrine, Long Time On Market For Hypotension, Goes To FDA Panel
The agency seeks counsel on whether elevation in blood pressure is sufficient clinical benefit to approve the literature-based NDA for West-Ward Pharmaceutical’s product, which is currently an unapproved drug.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.